444 related articles for article (PubMed ID: 30281871)
1. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
Kobayashi M; Tojo A
Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
[TBL] [Abstract][Full Text] [Related]
2. [Pathophysiology and treatment of adult Langerhans cell histiocytosis].
Tojo A; Kobayashi M
Rinsho Ketsueki; 2020; 61(9):1028-1034. PubMed ID: 33162496
[TBL] [Abstract][Full Text] [Related]
3. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
4. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
Satoh T; Smith A; Sarde A; Lu HC; Mian S; Trouillet C; Mufti G; Emile JF; Fraternali F; Donadieu J; Geissmann F
PLoS One; 2012; 7(4):e33891. PubMed ID: 22506009
[TBL] [Abstract][Full Text] [Related]
5. Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is a Neoplastic Process: Clinicopathologic and Molecular Study of 7 Cases.
Agaimy A; Bonert M; Naqvi A; Wang C; Trpkov K; Dettmar P; Wintzer HO; Stoehr R; Hes O; Williamson SR; Gibson IW; Hartmann A
Am J Surg Pathol; 2020 Dec; 44(12):1658-1665. PubMed ID: 32910018
[TBL] [Abstract][Full Text] [Related]
6. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
8. Langerhans cell histiocytosis: current advances in molecular pathogenesis.
Sconocchia T; Foßelteder J; Sconocchia G; Reinisch A
Front Immunol; 2023; 14():1275085. PubMed ID: 37965340
[TBL] [Abstract][Full Text] [Related]
9. [Status of Langerhans cell histiocytosis in children and adults].
Kudo K
Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
[TBL] [Abstract][Full Text] [Related]
10. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
12. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.
Egeler RM; Katewa S; Leenen PJ; Beverley P; Collin M; Ginhoux F; Arceci RJ; Rollins BJ;
Pediatr Blood Cancer; 2016 Oct; 63(10):1704-12. PubMed ID: 27314817
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
[TBL] [Abstract][Full Text] [Related]
14. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.
Zarnegar S; Durham BH; Khattar P; Shukla NN; Benayed R; Lacouture ME; Lavi E; Lyden DC; Diamond EL; Dunkel IJ; Abdel-Wahab O
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748614
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.
Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
Cell Commun Signal; 2015 Feb; 13():13. PubMed ID: 25889448
[TBL] [Abstract][Full Text] [Related]
16. Recurrent BRAF mutations in Langerhans cell histiocytosis.
Badalian-Very G; Vergilio JA; Degar BA; MacConaill LE; Brandner B; Calicchio ML; Kuo FC; Ligon AH; Stevenson KE; Kehoe SM; Garraway LA; Hahn WC; Meyerson M; Fleming MD; Rollins BJ
Blood; 2010 Sep; 116(11):1919-23. PubMed ID: 20519626
[TBL] [Abstract][Full Text] [Related]
17. [Elucidated pathogenesis and therapeutic prospects in Langerhans cell histiocytosis].
Morimoto A; Shioda Y; Sakamoto K; Kudo K; Imamura T; Kudo K
Rinsho Ketsueki; 2022; 63(5):373-382. PubMed ID: 35662160
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
[TBL] [Abstract][Full Text] [Related]
19. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
[TBL] [Abstract][Full Text] [Related]
20.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]